Q-omics provides the consensus-scored PLA2G4A profile across patient tissues and cancer cell-line models. PLA2G4A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLA2G4A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PLA2G4A RNA expression shows 18,539 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where PLA2G4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G4A survival associations across molecular data types. PLA2G4A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G4A RNA expression–survival associations across cancer types. High PLA2G4A expression shows unfavorable associations in UVM, LAML and LGG, but favorable associations in UCEC, KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for PLA2G4A RNA expression.
This table summarizes PLA2G4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G4A shows lower tumor expression in KIRC, KICH, THCA and BRCA and higher tumor expression in LUAD and PAAD. The KIRC box plot shows higher PLA2G4A RNA expression in normal versus tumor tissue (log2 FC = −1.568, t-test p < 0.001).
This table shows molecular features associated with PLA2G4A in patient tissues and cancer cell lines. In patient samples, PLA2G4A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
